Barriers to the access and use of rituximab in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia: A physician survey

Pharmaceuticals

Volumn 7, Issue 5, 2014, Pages 530-544

  Baer II, William H ^a   Maini, Archana ^b   Jacobs, Ira ^c  

^a ClinXus   (United States)

^b BROWARD HEALTH MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

Access; Biosimilar; Emerging markets; Rituximab

Indexed keywords

RITUXIMAB;

ARTICLE; BRAZIL; CHRONIC LYMPHATIC LEUKEMIA; DRUG COST; DRUG USE; HEALTH INSURANCE; HEMATOLOGIST; HUMAN; MEXICO; NONHODGKIN LYMPHOMA; ONCOLOGIST; PHYSICIAN ATTITUDE; PROTOCOL COMPLIANCE; REIMBURSEMENT; RUSSIAN FEDERATION; TURKEY (REPUBLIC); UNITED STATES;

EID: 84900407291     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph7050530     Document Type: Article

References (39)

1. Rituxan US Prescribing Information. Available online: http://www.gene.com/download/pdf/ rituxan_prescribing.pdf. (accessed on 17 October 2013).
2. MabThera EU Prescribing Information. Available online: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf. (accessed on 17 October 2013).
3. Vital, E.M.; Kay, J.; Emery, P. Rituximab biosimilars. Expert Opin. Biol. Ther. 2013, 13, 1049-1062.
4. Uchida, J.; Lee, Y.; Hasegawa, M.; Liang, Y.; Bradney, A.; Oliver, J.A.; Bowen, K.; Steeber, D.A.; Haas, K.M.; Poe, J.C.; et al. Mouse CD20 expression and function. Int. Immunol. 2004, 16, 119-129.
5. Tedder, T.F.; Engel, P. CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol. Today 1994, 15, 450-454.
6. Glennie, M.J.; French, R.R.; Cragg, M.S.; Taylor, R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44, 3823-3837.
7. Maloney, D.G. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 2012, 366, 2008-2016.
8. Cang, S.; Mukhi, N.; Wang, K.; Liu, D. Novel CD20 monoclonal antibodies for lymphoma therapy. J. Hematol. Oncol. 2012, 5, 64.
9. Czuczman, M.S.; Gregory, S.A. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk. Lymphoma 2010, 51, 983-994.
10. Hiddemann, W.; Kneba, M.; Dreyling, M.; Schmitz, N.; Lengfelder, E.; Schmits, R.; Reiser, M.; Metzner, B.; Harder, H.; Hegewisch-Becker, S.; et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106, 3725-3732.
11. Bachy, E.; Houot, R.; Morschhauser, F.; Sonet, A.; Brice, P.; Belhadj, K.; Cartron, G.; Audhuy, B.; Fermé, C.; Feugier, P.; et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 2013, 98, 1107-1114.
12. Herold, M.; Haas, A.; Srock, S.; Neser, S.; Al-Ali, K.H.; Neubauer, A.; Dölken, G.; Naumann, R.; Knauf, W.; Freund, M.; et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 2007, 25, 1986-1992.
13. Marcus, R.; Imrie, K.; Solal-Celigny, P.; Catalano, J.V.; Dmoszynska, A.; Raposo, J.C.; Offner, F.C.; Gomez-Codina, J.; Belch, A.; Cunningham, D.; et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 2008, 26, 4579-4586.
14. Pfreundschuh, M.; Trümper, L.; Osterborg, A.; Pettengell, R.; Trneny, M.; Imrie, K.; Ma, D.; Gill, D.; Walewski, J.; Zinzani, P.-L.; et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006, 7, 379-391.
15. Coiffier, B.; Thieblemont, C.; van Den Neste, E.; Lepeu, G.; Plantier, I.; Castaigne, S.; Lefort, S.; Marit, G.; Macro, M.; Sebban, C.; et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116, 2040-2045.
16. Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van Den Neste, E.; Salles, G.; Gaulard, P.; et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346, 235-242.
17. Robak, T.; Dmoszynska, A.; Solal-Céligny, P.; Warzocha, K.; Loscertales, J.; Catalano, J.; Afanasiev, B.V.; Larratt, L.; Geisler, C.H.; Montillo, M.; et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 2010, 28, 1756-1765.
18. Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A.M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Grünhagen, U.; et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010, 376, 1164-1174.
19. Oki, Y.; Younes, A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr. Hematol. Malig. Rep. 2010, 5, 135-139.
20. Dreyling, M.; Thieblemont, C.; Gallamini, A.; Arcaini, L.; Campo, E.; Hermine, O.; Kluin-Nelemans, J.C.; Ladetto, M.; le Gouill, S.; Iannitto, E.; et al. ESMO Consensus conferences: Guidelines on malignant lymphoma. part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann. Oncol. 2013, 24, 857-877.
21. Barnes, J.A.; LaCasce, A.S.; Feng, Y.; Toomey, C.E.; Neuberg, D.; Michaelson, J.S.; Hochberg, E.P.; Abramson, J.S. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: A retrospective analysis. Ann. Oncol. 2011, 22, 1859-1864.
22. Dimopoulos, M.A.; Gertz, M.A.; Kastritis, E.; Garcia-Sanz, R.; Kimby, E.K.; LeBlond, V.; Fermand, J.-P.; Merlini, G.; Morel, P.; Morra, E.; et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J. Clin. Oncol. 2009, 27, 120-126.
23. Schellekens, H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009, 2, i27-i36.
24. Mellstedt, H.; Niederwieser, D.; Ludwig, H. The challenge of biosimilars. Ann. Oncol. 2008, 19, 411-419.
25. Zelenetz, A.D.; Ahmed, I.; Braud, E.L.; Cross, J.D.; Davenport-Ennis, N.; Dickinson, B.D.; Goldberg, S.E.; Gottlieb, S.; Johnson, P.E.; Lyman, G.H.; et al. NCCN Biosimilars White Paper: Regulatory, scientific, and patient safety perspectives. J. Nat. Compr. Cancer Netw. 2011, 9, S1-S22.
26. Cai, X.; Wake, A.; Gouty, D. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development. Bioanalysis 2013, 5, 517-520.
27. Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 2002, 1, 457-462.
28. Megerlin, F.; Lopert, R.; Taymor, K.; Trouvin, J.H. Biosimilars and the European experience: Implications for the United States. Health Aff. (Millwood) 2013, 32, 1803-1810.
29. Patient Protection and Affordable Care Act of 2009, Pub. L. No. 111-148, Title VII, Subtitle A "Biologics Price Competition and Innovation Act of 2009", Section 7001-7003.
30. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the guideline on similar biological medicinal product. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/ WC500117987.pdf. (accessed on 4 November 2013).
31. Zelenetz, A.D.; Wierda, W.G.; Abramson, J.S.; Advani, R.H.; Andreadis, C.B.; Bartlett, N.; Bellam, N.; Byrd, J.C.; Czuczman, M.S.; Fayad, L.E.; et al. Non-Hodgkin's lymphomas. J. Natl. Compr. Cancer Netw. 2013, 11, 257-272.
32. Zhao, J.; Xu, Z.; Liu, D.; Lu, Q. Rituximab and new regimens for indolent lymphoma: A brief update from 2012 ASCO Annual Meeting. Cancer Cell Int. 2012, 12, 38.
33. Ghielmini, M.; Vitolo, U.; Kimby, E.; Montoto, S.; Walewski, J.; Pfreundschuh, M.; Federico, M.; Hoskin, P.; McNamara, C.; Caligaris-Cappio, F.; et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann. Oncol. 2013, 24, 561-576.
34. Qureshi, Z.P.; Magwood, J.S.; Singh, S.; Bennett, C.L. Rituximab and biosimilars-Equivalence and reciprocity. Biosimilars 2013, 2013, 19-25.
35. The World Bank. Available online: http://data.worldbank.org/country/india (accessed on 4 November 2013).
36. Lopes, G. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann. Oncol. 2013, 24, v13-v16.
37. Merron, A. Biosimilars Advisory Service: Physician Perspectives on G-CSFs and Monoclonal Antibodies in Oncology. Available online: http://bio-trends.com/Products-and-Services/ Report?r=basxxx0113. (accessed on 4 Novemeber 2013).
38. Shanafelt, T.D.; Madueme, H.L.; Wolf, R.C.; Tefferi, A. Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin. Proc. 2003, 78, 1340-1346.
39. Agency for Healthcare Research and Quality. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Available online: http://www.guideline.gov/content.aspx?id=37905 (accessed on 7 November 2013).